thymosin beta-4 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-20. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
== Moving wire IRMS == Moving wire IRMS is useful for analyzing carbon-13 ratios of compounds in a solution, such as after purification by liquid chromatography. The solution (or outflow from the chromatography) is dried onto a nickel or stainless steel wire. After the residue is deposited on the wire, it enters a furnace where the sample is converted to CO2 and water by combustion. The gas stream finally enters a capillary, is dried, ionized, and analyzed. This process allows a mixture of compounds to be purified and analyzed continuously, which can decrease the analysis time by a factor of four. Moving wire IRMS is quite sensitive, and samples containing as little as 1 nanomole of carbon can yield precise (within 1‰) results.
=== Pharmacokinetics === The bioavailability of levodopa is 30%. It is metabolized into dopamine by aromatic-l-amino-acid decarboxylase (AAAD) in the central nervous system and periphery. The elimination half-life of levodopa is 0.75 to 1.5 hours. It is excreted 70–80% in urine.
is found similarly. Substituting these nuclear masses into the Q-value equation, while neglecting the nearly zero antineutrino mass and the difference in electron binding energies, which is very small for high-Z atoms, we have
Sources: en.wikipedia.org
==== 1965 - 1992 ==== Following the assassination of Kennedy in 1963, India-US relations deteriorated gradually. While Kennedy's successor Lyndon B. Johnson sought to maintain relations with India to counter Communist China, he also sought to strengthen ties with Pakistan with the hopes of easing tensions with China and weakening India's growing military buildup as well. Relations then hit an all-time low under the Nixon administration in the early 1970s. Nixon shifted away from the neutral stance which his predecessors had taken towards India-Pakistan hostilities. He established a very close relationship with Pakistan, aiding it militarily and economically, as India, now under the leadership of Indira Gandhi, was leaning towards Soviet Union. He considered Pakistan as a very important ally to counter Soviet influence in the Indian subcontinent and establish ties with China, with whom Pakistan was very close. The frosty personal relationship between Nixon and Indira further contributed to the poor relationship between the two nations. Nixon also harbored sexist and racist sentiments against Indians, describing the empathetic attitude of the American public toward India as a "psychological disorder". During the 1971 Indo-Pakistani War, the US openly supported Pakistan and deployed its aircraft carrier USS Enterprise towards the Bay of Bengal, which was seen as a show of force by the US in support of the West Pakistani forces.
== Pathophysiology == TANGO2 plays role in mitochondrial β-oxidation, consequently in that disease, β-oxidation and ATP levels are reduced (especially under stress). Interestingly TANGO2 also might participate in retrograde ER-Golgi trafficking, consequently this process is slowed down in this disease, and the supplementation of TANGO2 has restored that process. According to one study, TANGO2 also might participate in autophagy process, which might be responsible for rhabdomyolysis in this disease.
Emerging evidence suggests that the gut microbiome may also provide predictive information for response to immune checkpoint blockade. In a multi-regional study 674 patients with resected high-risk melanoma receiving adjuvant immune checkpoint blockade, pre-treatment gut bacterial markers were associated with recurrence, with prediction performing best when patients were compared within groups matched for overall gut microbiome composition, suggesting that microbiome-based biomarkers may be informative but context dependent. PD-1 and PD-L1 inhibitors are closely related to CTLA4 (cytotoxic T-lymphocyte-associated protein 4) inhibitors, such as ipilimumab. PD-1 and CTLA-4 are both expressed on activated T cells, but at different phases of immune response. Current clinical trials are evaluating anti-PD-1 and PD-L1 drugs in combination with other immunotherapy drugs blocking LAG3, B7-H3, KIR, OX40, PARP, CD27, and ICOS.
Pasteur solved the mystery of polarized light acting differently with chemically identical crystals and solutions by discovering the phenomenon of molecular asymmetry, that is that molecules could be chiral and exist as a pair of enantiomers. Pasteur's method was to physically separate the crystals of a racemic mixture of sodium ammonium tartrate into right- and left-handed crystals, and then dissolve them to make two separate solutions which rotated polarized light in opposite directions. Pasteur's research was in part informed by considerations of molecular symmetry. Pasteur also proposed two other methods for the isolation of optically active enantiomers from racemic mixtures: by the use of optically active bases, e.g. strychnine, or by means of living organisms, e.g. bacteria or yeasts. William Thomson (Lord Kelvin) introduced the word "chiral" in 1904 to describe handed figures. Objects that do not exhibit optical isomerism are said to be "achiral", that is their image in a plane mirror can be made congruent with itself. The term chirality has almost completely displaced the term "dissymmetry" which was used by Pasteur.
Sources: en.wikipedia.org
== History == Rosetta Genomics was founded by Isaac Bentwich in 2000 to pursue commercial applications of microRNA research. The company had its IPO on March 6, 2007, and is traded on the NASDAQ. Rosetta Genomics expects the funds raised to advance its microRNA-based diagnostic and therapeutic cancer products through initial clinical validation, defined as success in identifying the specific biomarker panels via blinded tests of samples supplied by medical institutions. In 2016, the company was ranked #27 on the Deloitte Fast 500 North America list. In 2017, the company was sold for $10 million to private US company Genoptix. On 31 May 2018, it was announced that Rosetta Genomics filed for Chapter 7 bankruptcy.
=== Legal status === Esketamine is a Schedule III controlled substance in the United States. Esketamine is a controlled drug In The United Arab Emirates due to its potential for abuse, its use is only under strict medical supervision which is only available on government hospitals in the country, and its use only approved for treatment-resistant depression registered under the trademark Spravato.
On April 25, 2023, Carrier Global announced that it intended to acquire the HVAC division Viessmann Climate Solutions from the Viessmann Group and divest its Commercial Refrigeration business and most of its Fire & Security businesses. In December 2023, Carrier Global sold its security businesses LenelS2, Supra and Onity to Honeywell for approximately $5 billion. In March 2025, Carrier Global declared to sell its Industrial Fire division to Sentinel Capital Partners in a $1.43 billion deal.
Bacon – some forms of bacon are dried, such as freeze-dried bacon. Bakkwa – a Chinese salty-sweet dried meat product similar to jerky. Bakkwa is made with a meat preservation and preparation technique originating from China. Bayonne ham – an air dried salted ham that takes its name from the ancient port city of Bayonne in the far South West of France, a city located in both the cultural regions of Basque Country and Gascony. Jambon de Bayonne has PGI status. It is a slightly sweet, delicately flavored meat with little salt to the taste. Biltong – a variety of cured meat that originated in Southern Africa, various types of meat are used to produce it, ranging from beef and game meats to fillets of ostrich from commercial farms. It is typically made from raw fillets of meat. Black Forest ham – a variety of dry-cured smoked ham, a pork product, produced in the Black Forest region of Germany. Ham is the thigh and rump from the haunch of a pig or boar. It is the best-selling smoked ham in Europe. Borts – a Mongolian air-dried meat with preparation involving cutting the meat into long strips which are hung in the shade. Bresaola – air-dried, salted beef that has been aged two or three months until it becomes hard and turns a dark red, almost purple color. It is made from top (inside) round, and is lean and tender, with a sweet, musty smell. It originated in Valtellina, a valley in the Alps of northern Italy's Lombardy region. Brési – beef which has been salted, dried and smoked over a period of three months, which is made in the Department of Doubs.
== Creation and different nominations == 1943 - 1947 : creation of the 9th Colonial Infantry Division (French: 9e Division d'Infanterie Coloniale, 9e D.I.C) 1963 - 1976 : designated as 9th Brigade (French: 9e Brigade, 9eB) 1976 - 1999 : designated as 9th Marine Infantry Division (French: 9e Division d'Infanterie de Marine, 9e D.I.Ma) 1999 - 2013 : designated as 9th Light Armoured Marine Brigade (French: 9e Brigade Légère Blindée de Marine, 9e B.L.B.Ma) 2013–present : designated as 9th Marine Infantry Brigade (French: 9e Brigade d'Infanterie de Marine, 9e B.I.Ma)
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.